Submission Deadline 11/10/2026
Fiscal Capacity $50,135,013
HHS-NIH11 Grant — Key Facts
Opportunity Number RFA-NS-26-001
Agency HHS-NIH11
Application Deadline 11/10/2026
Award Amount $50,135,013
Status Posted
Sector Health
Cost Sharing Not Required

Fiscal Parameters & Taxonomy

Authority HHS-NIH11
Status Posted

Who Can Apply

County governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) State governments Small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Independent school districts For profit organizations other than small businesses

Eligibility Intelligence

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial (designed to provide pivotal data to support a marketing application) supported by a small business concern that is the FDA-designated sponsor of a drug or biological product which is the subject of an IND under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) to prevent, diagnose, mitigate, treat, or cure ALS. The definition of a small business concern can be found in section 3(a) of the Small Business Act (15 U.S.C. 632(a)).Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Program Description

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.

CFDA Programs

93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders

Agency Contact

ALS Program NINDSALSMailbox@mail.nih.gov

✉ NINDSALSMailbox@mail.nih.gov

📞 301-402-2541

Related Intelligence Guides

In-depth editorial guides covering this agency's programs, eligibility requirements, and application strategies.

GrantMetric Intelligence Systems — Independent federal grant intelligence platform. Not affiliated with Grants.gov, the U.S. Department of Health & Human Services, or any government agency. Grant data is sourced from the Grants.gov API for informational purposes only; always verify opportunity details directly with the funding agency before applying. Some links on this site are affiliate links — we may earn a commission at no additional cost to you. Full Disclaimer  ·  Last Reviewed: May 2026  ·  Data Methodology